Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Buprenorphine / Naloxone; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Eosinophilic Esophagitis
Interventions: AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension; Drug
Lead sponsor: AQILION AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obscure Gastrointestinal Bleeding
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn's Disease
Interventions: Capsule Endoscopy; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy
Interventions: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg, Macrobid® Capsules 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Barrett Esophagus, Barretts Esophagus With Dysplasia
Interventions: OFDI capsule imaging; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Tasimelteon Oral Capsule, Tasimelteon Oral Suspension; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Uterine Fibroids (UF)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Influenza, Human
Interventions: over-encapsulated oseltamivir, oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules); Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: MS1819, Porcine PERT; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more

Conditions: Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic, Chronic
Interventions: PCI-24781; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 4
States / cities: Greenbrae, California • Chicago, Illinois • Nashville, Tennessee + 1 more

Conditions: Thyroid Cancer, Postsurgical Hypothyroidism
Interventions: Levothyroxine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: bexarotene; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Houston, Texas • San Antonio, Texas

Conditions: Campylobacter Infection
Interventions: Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Brookline, Massachusetts

Conditions: Gout, Hyperuricemia
Interventions: LC350189 Tablet, LC350189 Capsule; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
Interventions: TKI258; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 21
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more

Conditions: Atopic Dermatitis
Interventions: 5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more

Conditions: Onychomycosis
Interventions: SUBA-itraconazole, Itraconazole, Placebo; Drug
Lead sponsor: Halcygen Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more

Conditions: Stage IV Breast Cancer, Recurrent Breast Cancer
Interventions: antineoplaston A10, methotrexate, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, chemotherapy, complementary and alternative therapy, differentiation therapy; Drug · Procedure
Lead sponsor: Burzynski Research Institute; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Adult Subjects
Interventions: Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Clostridium Difficile-associated Diarrhea (CDAD)
Interventions: Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: Up to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more

Conditions: Posterior Knee Infiltration
Interventions: Ropivacaine with Epinephrine, Ropivacaine; Drug
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Search by objective public record fields.

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

Diagnostic Evaluation of Obscure Gastrointestinal Bleeding

Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease

Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg

Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Posterior Capsular Injection With Femoral Nerve Block for Total Knee Arthroplasty